C0021756||interleukin-2
C0021758||-4
C0085295||-10
C0011311||dengue
C0011311||Dengue
C0003723||arboviral disease
C0449943||serotypes
C0011315||dengue virus
C0699748||pathogenesis
C0011311||dengue
C0079189||pro-
C0079189||anti-inflammatory cytokines
C0699748||immune pathogenesis
C0011311||dengue
C0021756||Interleukin (IL)-2
C0034819||IL-2 receptor
C0021758||IL-4
C0079189||pro-inflammatory
C0085295||IL-10
C0079189||anti-inflammatory cytokines
C0079189||cytokines
C0011311||dengue infection
C2603343||study
C0021756||IL-2
C0021758||-4
C0085295||-10
C0011311||dengue infection
C0010362||cross-sectional study
C2603343||study
C0178913||blood samples
C0011311||dengue
C0011311||dengue
C2699541||cytokines levels
C0021756||IL-2
C0021758||-4
C0085295||-10
C0014441||ELISA
C0011311||dengue infection
C0043237||WHO
C0037585||SPSS version 21
C0683757||IBM
C0027977||New York
C0041703||United States
C0011311||dengue
C1446409||positive
C0011311||nonsevere dengue
C0011311||dengue
C0229671||serum
C2697785||levels of IL-4
C2697758||-10
C0011311||dengue
C0011311||nonsevere dengue
C0229671||serum
C2697779||IL-2 levels
C0011311||dengue
C2697785||IL-4
C2697758||-10 levels
C0005516||marker
C0011311||dengue
C1318963||preparedness
C0087111||treatment
C0011311||dengue